Table 1 Baseline characteristics of the SWEFOT participants for all patients and also within each treatment group
All SWEFOT patients (N = 487) | All study patients (N = 159) | MTX responders (N = 49) | Triple therapy (N = 55) | Combination MTX + INF (N = 55) | p-value | |
|---|---|---|---|---|---|---|
Disease duration, months | 6.16 (3.20) | 6.08 (3.20) | 5.86 (3.12) | 6.00 (3.10) | 6.35 (3.40) | 0.79 |
Sex, female | 70.6 (344) | 72.3 (115) | 63.3 (31) | 74.5 (41) | 78.2 (43) | 0.21 |
ACPA pos.% (n) | 63.7 (310) | 60.3 (91) | 55.6 (25) | 62.3 (33) | 62.3 (33) | 0.74 |
RF pos.% (n) | 68.4 (333) | 69.1 (96) | 68.2 (30) | 71.4 (35) | 67.4 (31) | 0.90 |
DAS 28 | 5.73 (1.01) | 5.70 (1.00) | 5.23 (0.99) | 5.99 (1.02) | 5.85 (0.92) | <0.001*/0.004**/1.0^ |
ESR (mm) | 39.8 (28.1) | 38.6 (26.6) | 31.2 (24.4) | 49.3 (27.7) | 34.4 (24.3) | 0.001*/1.0**/0.008^ |
CRP (mg/L) | 33.7 (42.4) | 35.1 (40.4) | 27.3 (40.1) | 47.1 (41.2) | 29.8 (37.7) | 0.04*/1.0**/0.07^ |
HAQ | 1.19 (0.58) | 1.19 (0.59) | 0.97 (0.47) | 1.35 (0.65) | 1.25 (0.57) | 0.003*/0.04**/1.0^ |
T-SHS | 4.54 (8.01) | 4.79 (7.85) | 3.04 (6.00) | 5.98 (8.53) | 5.08 (8.37) | 0.07 |
ES | 1.91 (3.75) | 1.99 (3.56) | 1.71 (2.87) | 2.43 (4.32) | 1.76 (3.21) | 0.52 |
DXR-BMD (g/cm2) | ---- | 0.58 (0.08) | 0.59 (0.08) | 0.57 (0.06) | 0.56 (0.08) | 0.14 |